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Navigating the research–clinical interface in genomic
medicine: analysis from the CSER Consortium
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Wendy K. Chung, MD, PhD4, Ellen Wright Clayton, MD, JD5, Robert C. Green, MD, MPH6,
Julie Harris-Wai, PhD, MPH7, Gail E. Henderson, PhD8, Gail P. Jarvik, MD, PhD2,9,
Barbara A. Koenig, PhD10, Lisa Soleymani Lehmann, MD, PhD11,12, Amy L. McGuire, JD, PhD13,
Pearl O’Rourke, MD14, Carol Somkin, PhD15, Benjamin S. Wilfond, MD16 and
Wylie Burke, MD, PhD2,17
Purpose: The Clinical Sequencing Exploratory Research (CSER)
Consortium encompasses nine National Institutes of Health–
funded U-award projects investigating translation of genomic
sequencing into clinical care. Previous literature has distinguished
norms and rules governing research versus clinical care. This is the
first study to explore how genomics investigators describe and
navigate the research–clinical interface.
Methods: A CSER working group developed a 22-item survey. All
nine U-award projects participated. Descriptive data were tabulated
and qualitative analysis of text responses identified themes and
characterizations of the research–clinical interface.
Results: Survey responses described how studies approached
the research–clinical interface, including in consent practices,
recording results, and using a research versus clinical laboratory.
Responses revealed four characterizations of the interface: clear
separation between research and clinical care, interdigitation of
the two with steps to maintain separation, a dynamic interface,
and merging of the two. All survey respondents utilized at least
two different characterizations. Although research has traditionally
been differentiated from clinical care, respondents pointed to
factors blurring the distinction and strategies to differentiate the
domains.
Conclusion: These results illustrate the difficulty in applying
the traditional bifurcation of research versus clinical care to
translational models of clinical research, including in genomics.
Our results suggest new directions for ethics and oversight.
Genet Med advance online publication 31 August 2017
Key Words: exome sequencing; genome sequencing; research
ethics; translational ethics; translational genomics
INTRODUCTION
Translational genomics straddles the domains of research and
clinical care.1 Research projects such as those included in the
Clinical Sequencing Exploratory Research (CSER) Consor-
tium funded by the National Institutes of Health (NIH) aim to
create an evidence base for successful integration of genome
and exome sequencing into clinical care.2 CSER research
projects were funded to “address critical questions about
the application of genomic sequencing to clinical care of
individual patients.”3 Importantly, the intent of the CSER
projects is not discovery but clinical implementation of
genome-scale sequencing. Thus, the CSER projects may be
uniquely positioned to identify challenges faced at the
research–clinical interface.
The CSER projects investigate the clinical utility of
sequencing in a range of clinical settings involving both
pediatric and adult participants. Most of the studies enroll
patients with clinical indications related to cancer, neuro-
developmental disorders, cardiovascular disease, or rare
genetic disorders, but CSER projects include an investigation
of genomic screening in healthy people and the use of
sequencing in carrier testing for individuals planning
a pregnancy. Investigators confront a range of issues at the
interface between research and clinical care, including
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whether to use research or clinical laboratories for sequencing,
whether to record results in the research or medical record,
what findings to offer back to patient-participants, and what
services and follow-up to charge to research budgets or
submit for insurance reimbursement.4,5
Translational genomics is not alone in raising issues at the
interface between research and clinical care; clinical research
investigating the effectiveness of a drug or other intervention
in affected patients may raise such issues as well.6 However,
the literature on translational genomics reflects a growing
challenge to the traditional view that research and clinical care
are distinct activities that should be governed by separate
norms and rules.1,7–10 Beginning with the Belmont Report11
and emergence of regulations governing the conduct of
research with human participants,12,13 the conventional view
has been that there are fundamental differences between
research and clinical care, necessitating distinctive ethical
frameworks and regulatory oversight.14 (See Table 1).
Research has been defined by the Common Rule as “a
systematic investigation…designed to develop or contribute
to generalizable knowledge,” through a process that might or
might not offer potential benefit to participants, with
safeguards provided by institutional review board (IRB)
oversight, extensive consent requirements, and limits on
acceptable research. In clinical care, on the other hand,
clinicians bear a fiduciary duty to act primarily for the benefit
of the patient in keeping with established standards of
professionalism and ethics. A large literature addresses the
potential for confusion regarding the goals of research and
clinical care and offers recommendations for maintaining the
distinction.15–19
The rise of translational research is among the develop-
ments that have raised new questions about the viability and
future of this dichotomous approach.1,7,9 When research is
designed to investigate clinical integration of emerging
interventions such as genomic sequencing, the goals of
advancing generalizable knowledge and benefiting those
who undergo sequencing can be closely intertwined. While
a literature has begun to emerge on these issues,1,20,21 no prior
studies have documented how genomics investigators see the
relationship of research to clinical care, what challenges they
encounter when conducting translational genomics research,
and what solutions they are deploying to navigate these issues.
We report here perspectives from the nine CSER studies.
MATERIALS AND METHODS
Survey development
A working group of the CSER Consortium developed a survey
(see Supplementary Material online) consisting mainly of
short-answer questions, both closed- and open-ended, to
assess factors relevant to the research–clinical interface. Items
were based on literature review and solicited experiences of
consortium investigators. The survey included 16 specific
questions about the respondent’s study, including consent
procedures; involvement of research and clinical personnel;
disclosure of results; where results are recorded (in the
medical record, research record, or both); procedures covered
by the research budget versus billed to insurers; and legal
issues raised in study design or implementation, plus use of a
research or CLIA-certified clinical laboratory. Respondents
were also asked to answer six general questions eliciting their
views on the interface between genomic research and clinical
care. They could add additional comments. A draft survey was
piloted at one of the 9 CSER sites to assess comprehension
and survey completeness, with revision based on feedback.
Survey completion
Each CSER principal investigator was asked to respond or
designate a respondent to complete the survey. After the pilot,
all other CSER U-award projects completed the survey in
February/March 2016, for a total of nine completed surveys.
Each site was subsequently asked to confirm the list of results
returned to participants in Table 2; seven of nine sites made
minor corrections.
Table 1 Conventional distinctions between research with human participants and clinical care of patients
Areas of contrast Research Clinical care and laboratory practice
Personnel Investigator and participant Clinician and patient
Goals Seek generalizable knowledge Advance patient well-being
Professionals’ core duty Duty to conduct research in compliance with scientific and
ethical standards
Duty of clinical care in keeping with standards of care
Key sources of standards Common Rule, FDA regulations on human subjects research,
Nuremberg Code, Declaration of Helsinki, CIOMS
Guidelines, Good Clinical Practice
Established standards of care, clinical guidelines, clinical
laboratory standards (e.g., CLIA, state law), malpractice
adjudication
Primary mechanisms to
enforce standards
Prior IRB review and ongoing oversight, research funder
review and oversight, federal OHRP investigation, FDA
oversight of drugs and devices
Licensure, discipline, and clinical privileges; Joint Commission
accreditation; laboratory certification and inspection;
malpractice adjudication
Funding Research grants and contracts, industry funding of research Payers including patients, insurers, state and federal
programs
Records Research records Medical records
CIOMS, Council for International Organizations of Medical Sciences; CLIA, Clinical Laboratory Improvement Amendments; FDA, Food and Drug Administration; IRB, insti-
tutional review board; OHRP, Office for Human Research Protections.
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Table 2 Results returned in CSER U-award studies
Site Indication-
specific
findings
Tumor analysis Actionable
secondary or
incidental findings
Pharmacogenetic
findings
Carrier status Nonactionable
secondary or
incidental findings
Other VUS
1 Yes Yes ACMG plus
additional
Yes Yes (opt-out) No All tumor VUS;
germ-line VUS only
related to indication
2 Yes Select variants
associated with
chemotherapy
recommendations
ACMG plus
additional
Select gene–drug pairs 10 conditions No VUS related to
indication and for
medically actionable
genes that family
analysis would
clarify
3 Yes No ACMG plus
additional
Yes Yes Yes Risk variants for select
common complex
conditions based on
GWAS and red blood
cell/platelet antigen
typing
VUS related to
indication and VUS
favor pathogenic
regardless of
indication
4 Yes No ACMG plus
additional
No 3 conditions plus
OMIM genes for
which participating
parents are both
carriers
No VUS related to
indication
5 Yes No Locally determined
list of actionable
conditions
Yes (opt-in) Yes (opt-in) Yes (opt-in), including
rare but highly penetrant
variants for serious
nontreatable conditions
Variants for risk in
select common complex
conditions based on
GWAS (opt-in)
VUS related to
indication
6 Yes Actionable or
potentially actionable
somatic variants with
focus on therapy
ACMG plus
additional
No Yes No VUS related to
indication
7 Yes No ACMG plus
additional (opt-in)
No Carrier status is
focus of study
No Variants in
mitochondrial genes
No
8 Yes Yes Custom list of 2,000
plus genes
Yes No VUS related to
indication
9 Yes Yes Yes No No No No
ACMG, American College of Medical Genetics and Genomics; CSER, Clinical Sequencing Exploratory Research Consortium; GWAS, genome-wide association studies; VUS, variants of uncertain significance.
“ACMG” refers to the roster of 56 secondary findings in Green et al.22
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Data analysis
Descriptive data from 16 questions on specific components of
the respondent’s study design were compiled (by research
coordinator Jeffrey Ou) and analyzed by two working group
members (S.M.W. and W.B.). Responses drawn primarily
from six general questions about the research–clinical inter-
face, but also from text responses to other questions, were
analyzed qualitatively to ascertain how the research–clinical
interface was described. Close reading of the text responses by
three working group members (S.M.W., W.B., and G.E.H.)
identified a continuum of characterizations of the research–
clinical interface within the CSER studies, ranging from
clear separation of research and clinical care activities to
a full merger of the two. Four codes were defined representing
points on the continuum: (1) clear separation of research
and clinical activities; (2) interdigitation of the two, with
steps taken to maintain the distinction; (3) a dynamic
border between the two, subject to negotiation and case-by-
case resolution; and (4) full merger. Two working group
members (W.B. and J.H.-W.) coded the text responses
independently. Coding disagreements were resolved by
consensus.
RESULTS
Informed consent
Participants in all CSER projects signed informed consent
forms for participation in the research. Some projects
nonetheless reported participant confusion between research
and clinical care:
We make a concerted effort to distinguish and separate
these [research and clinical care] activities in our descrip-
tion of study participation during the informed consent
conversation as well as through the consent document,
however clearly some confusion remains…. [Site 2]
Our subjects frequently complete multiple consents
including treatment trials as well as consent for
procedures, bone marrow biopsies, surgeries at the same
time. I think that [they] can get confused among the
studies or the differences between pure research and pure
clinical. [Site 1]
Some studies, however, reported that participants had limited
or no confusion between research and clinical care:
It seems generally clear to our participants that
they’re engaged in research that might have clinical
Implications [sic]. This is the norm in clinical research.
I think that our lack of problems has been facilitated,
in part, by having a physically separate area in which
participants are consented and in which results are
returned. In addition, we take care to distinguish the
research-generated results from the clinically confirmed
results and also make this distinction in the informed
consent session. [Site 5]
In keeping with this response, five of the nine projects
reported that they utilized research space or a separate visit to
complete the research consent procedures.
The consent takes place in research space and is prior to
the delivery of care. [Site 3]
Clinician and researcher roles
Clinicians participated in study design in eight of nine studies,
provided results to participants in all studies, and delivered
care following research testing in four of nine studies. Eight
of nine studies also involved some enrollment of clinicians
as participants, with interviews of referring clinicians or
observation of clinician decision-making following testing.
For six of the nine studies, at least some of the research
procedures occurred in clinical settings, for example obtaining
samples for research-related testing concurrent with delivery
of clinical care.
Role ambiguity was noted in six of nine studies. This is
due in part to the fact that some personnel have both
clinical care and research roles, and may find it challenging
to navigate between the two. One study reported:
[W]e have intentionally chosen to “hand off” patient
management to the clinical care team following results
disclosure by the research team. Sometimes it is difficult to
draw this line distinctly because the care is being handed-
off from one genetic counselor (in research setting) to a
different genetic counselor (in clinical setting), and the
genetic counselors on the study team have these same roles
as part of the clinical team on different days of the week—
and, in fact, could be the provider that the patient is
referred to. [Site 7]
However, some studies did not find significant con-
fusion about the roles played by research and clinical
personnel:
[W]e have not experienced ambiguity for issues like
families asking the research team questions they should
be asking their provider. [Site 4]
Disclosure of primary results and secondary findings
The projects varied in the categories of results disclosed
to participants (Table 2). All projects disclosed results related
to the clinical indication for which the participant was
enrolled and most also returned variants of uncertain
significance that were related to the clinical indication.
All returned medically actionable secondary (or incidental)
findings as well, usually a list generated by the study team
that included some or all of the 56 genes recommended
by the American College of Medical Genetics and Genomics
in 2013 for return of secondary findings in clinical
sequencing22 (a list revised in 2016),23 plus additional genes
determined to generate actionable medical findings.4 Each
of the projects also returned different combinations
of further genomic findings. Projects reported differing
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strategies for navigating the research–clinical interface in
results disclosure:
Provider participants decided if they wanted to see their
patients for the results disclosure session in research
space or in their clinical space as part of a regular clinical
appointment. Most of the results disclosure visits
occurred as part of a clinical visit in the clinical space,
but a few were scheduled on a case-by-case basis in the
research space. [Site 3]
Participants are returned research results by research
personnel – study genetic counselor [sic] and, when
necessary/available an MD clinical geneticist. [Site 2]
Placement of results in the medical record
Projects varied in placement of study results in the medical
record. Five projects placed all research results in the medical
record; two projects placed only selected results. One project
noted that primary findings related to the participant’s
medical indication would be placed in the medical record if
requested by the participating family. Another project sought
specific consent from participants for the placement of
diagnostic or medically actionable research findings in the
medical record. One project noted:
Since our results are all placed in the medical record and
the information is used by their clinicians there is heavy
overlap [between research and clinical]. [Site 1]
Payment for services
The question of what services should be billed to the research
study versus insurers and clinical payers was confusing to
some participants:
Participants have expressed confusion regarding what
testing is billed to their insurance and what testing is
being covered by the research study and some seem not to
realize that two tests are being done. [Site 2]
Respondents reported circumstances in which funding was
split, such as when clinical payers declined payment leading
the research team to fund a test instead. Thus, some projects
responded to payer decisions or negotiated, in a dynamic
resolution of whether research or clinical funding would cover
the cost:
Any downstream care as a result of the research is
clinical care…. If a pregnant woman and her partner are
found to be a carrier of the same condition, additional
testing like amniocentesis or [chorionic villus sampling]
would be part of her medical benefits. The study had
thought expedited partner testing due to a pregnancy
would be clinical care, but the insurer disagreed that
expedited partner testing should be a covered benefit.
Thus, expedited partner testing is now part of the
research activities. [Site 7]
Legal, regulatory, and ethical issues considered
The survey respondents were queried about any legal issues
considered in the design or implementation of their CSER
project. A recurring issue was determining whether results
returned to participants had to originate from a CLIA-
certified laboratory. Three studies utilized a research labora-
tory, with CLIA laboratory confirmation of any results
returned to participants. One study developed a CLIA-
certified laboratory to handle research assays during the
course of the study. The remaining five studies utilized a
CLIA-certified laboratory throughout the study.
However, one respondent noted:
The return of non-CLIA data continues to be a HUGE
issue. I think that ethically it is clear that subjects/parents
want research data, I think they have a right to it and in
particular the fact that some IRB’s [sic] absolutely refuse
disclosure and others allow it makes the situation,
particularly for a multi-institutional study, extremely
difficult. [Site 1]
One study reported a request from a participating family for
raw genomic data from the study. Researchers complied with
the request because of 2014 regulatory revisions allowing
Table 3 Characterizations of the research–clinical interface
Characterization of interface Explication
1. Research and clinical care seen as distinct Research components are clearly designated and differentiated from clinical care (e.g., consent
for participation is sought by research personnel in space dedicated to research)
2. Research and clinical care seen as distinct but
interdigitated
Despite differentiation between research and clinical care in study design, the mixing of
research and clinical care leads to potential confusion, prompting efforts to distinguish the two
domains (e.g., avoiding having the clinician seek research consent; research team intentionally
chooses to “hand off” management to clinical team after return of research results)
3. Negotiated or dynamically evolving interface
between research and clinical care
Decisions related to research and clinical care activities are made in a negotiated or dynamically
evolving way (e.g., determining which results to disclose to a participant or whether the
research budget will cover costs of testing)
4. Translational merger of research and clinical care Research and clinical care cannot be separated (e.g., study results are used to direct clinical
care)
Bolded selected words signify differences among the 4 characterizations.
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patients direct access to laboratory findings,24 but asked the
family to sign a waiver and pay for the costs of transmission.
Two studies noted discussion of potential malpractice
concerns, one related to return of results, the other to
potential difficulties in accessing follow-up clinical care. One
study reported developing a form to allow participants to
designate a recipient for their test results if the participant
died before receiving results. One study noted lengthy
discussion about the return of information concerning
adult-onset disorders to its pediatric population.
Characterizations of the research–clinical interface
Analysis of our survey responses suggests four characteriza-
tions of the research–clinical care interface in translational
research, arrayed along a continuum. These characterizations
range from the view that research and clinical care are fully
distinct to the view that research and clinical are fully merged
(displayed in Table 3).
As depicted in Table 4, all CSER sites deployed at least two
characterizations. Responses from all sites included answers
recognizing the distinction between research and clinical care
(characterization 1), and described steps taken to reinforce the
difference between research and clinical care in the face of
potential confusion (characterization 2). However, the
majority of sites also submitted responses characterizing the
research–clinical interface as dynamic or the two spheres as
merged. Seven of nine sites revealed a process involving
dynamic negotiation to determine whether a process (such as
payment for testing or follow-up) would be considered
research or clinical care (characterization 3), and six of nine
sites offered responses that characterized research and clinical
care as merged rather than separate spheres (characterization
4). The four characterizations are further described below.
Clear distinction between research and clinical care
(characterization 1). At one end of the continuum, the
distinction between research and clinical care is readily
apparent. For example, CSER studies sometimes enroll
patients referred by a different clinical institution, allowing
for a clear separation of research activities from clinical care.
All CSER studies include informed consent for research
procedures, and these are specified in research protocols.
Interdigitation of research and clinical care, with steps taken
to maintain the distinction (characterization 2). In many
instances, however, research and clinical activities occur in
the same location or are administered by personnel who
have both clinical and research roles. In these settings,
responses to several questions noted an obligation on the part
of researchers to clearly communicate differences between
research and clinical care. Thus, researchers in several CSER
studies chose to conduct informed consent or other research
procedures in a dedicated research space, or limit research
activities of clinicians, to help participants to distinguish
research activities from clinical care.
In contrast to the first two characterizations, which
treat research and clinical care as separate spheres and take
steps to maintain the distinction, the third and fourth
characterizations reject a strict separation. Instead, they treat
the relationship between research and clinical care as a
dynamically evolving interface on a case-by-case basis or treat
the two domains as merged.
Negotiated or dynamically evolving interface (characteri-
zation 3). Some survey responses revealed case-by-case
decision-making in which processes may be characterized as
either clinical or research based on negotiation and dynamic
response to events. In one study, a variant review committee
had been established to determine which research results
would be disclosed to participants; however, treating clin-
icians retained the right and responsibility to make the final
decision about which variants were disclosed. Another study
established a research fund that could reimburse participants
if insurance coverage was not available for tests needed to
qualify for study participation.
Translational merger of research and clinical care (charac-
terization 4). At the other end of the continuum, a number of
survey responses noted that research and clinical care are
merging and rejected the idea that these are separate spheres.
CSER research provides clinical benefit to at least some
participants by generating information that can be used
in clinical care. At the same time, sequencing can produce
new genomic discoveries prompting further research.
Several respondents reflected on the merger of research and
clinical care:
We believe [the CSER studies] are intrinsically both
[research and clinical care]. Given the nature of the data
generation and analysis process and the regular rates of
change in genome interpretation, each family is in a very
real sense a research project. However, the consequences
of the results are often of substantial and direct clinical
impact, and thereby these efforts are also clinical care.
[Site 4]
…I think [the distinction between research and clinical
care] is a false dichotomy. [Site 1]
Table 4 Summary of coding distribution for text responses
to survey questions across 4 characterizations of the
research–clinical interface, by site
Site (1)
Distinct
(2)
Interdigitated
(3)
Dynamically
evolving
(4)
Merger
1 X X X X
2 X X X X
3 X X X X
4 X X X X
5 X X
6 X X X X
7 X X X
8 X X X
9 X X X
“X” indicates at least one response corresponding to the characterization indi-
cated.
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Respondents also noted that blending of research and clinical
care stems in part from the state of genomic science.
Because we still do not understand penetrance in the
genomic space, we do not know what clinical recom-
mendations should be made as the result of variants
detected by a CLIA approved research study, the line
between what is “investigational” vs what is true clinical
care is still blurred. [Site 3]
The entire field of genomic diagnostics has been
operating on the research/clinical interface, in that our
procedures and knowledge are constantly evolving. While
in some sense this is a problem, it is what has been
pushing the field forward. [Site 8]
DISCUSSION
CSER investigators report a range of experiences in navigating
the research–clinical interface. The question of how to
conceptualize, plan for, and deal with this interface appears
to arise in multiple contexts, from design of the study through
execution and follow-up. CSER approaches to these issues
appear to reflect a community of genomics investigators
addressing multiple challenges at the research–clinical
interface.
Continuum of characterizations
Our results also revealed four characterizations of the
research–clinical interface as summarized in Table 3. These
ranged from the traditional, dichotomous view of two
separate spheres to the view that research and clinical care
are fully merged in CSER projects, which raises a number of
important questions. Different characterizations occurred in
answers from each study, with all studies including at least
two of the four.
The first question is why we see these four ways of thinking
about the research–clinical interface, instead of just one way.
The range of characterizations—and especially the third and
fourth ones, rejecting a fixed boundary between research and
clinical care—may suggest that we are seeing the emergence
of a translational research perspective that focuses on how
best to make the transition from the bench to the bedside. A
number of authors have called for the development of a more
translational approach to research ethics that deals explicitly
with increasingly blended approaches to research and clinical
care without losing sight of protections needed for research
participants.1,25,26
Finally, the continuum evident in these survey responses
invites consideration of whether current translational geno-
mics research, especially involving indication-based sequen-
cing in patients with suspected genetic conditions, makes
research and clinical care difficult to differentiate. While
blending of the two activities occurs in much clinical research,
it is likely to be most evident for emerging technologies with
the potential to yield clear benefit for some participants but
not all, leading to uncertainty about optimal use and justifying
research. The definitive diagnosis or clear treatment guidance
produced for some CSER participants exemplifies why
research and clinical care are difficult to separate. Sequencing
can also generate genomic discovery and new research
questions. Thus, translational genomics powers both clinical
integration and further research.1,27
Examination of how investigators view the research–clinical
interface in genomic research beyond CSER studies and in
realms of translational research beyond genomics would be
illuminating. The larger genomics research community may
show even greater diversity in approach. Beyond genomics, a
blurred interface may characterize any clinical research
involving interventions showing clear benefit for some
patients but requiring additional research to clarify benefits,
harms, and best practices for clinical integration.
Practical implications
The fact that six of the nine CSER studies described a merger
of research and clinical care, at least in response to some
survey questions (see Table 4), raises important questions
about the conduct of such translational genomics studies.
First, this perceived merger challenges the conventional
wisdom that investigators should emphasize that research
differs from clinical care, as research seeks generalizable
knowledge, while the sole aim of clinical care is to advance
each patient’s welfare. The conventional dichotomy of
research and clinical care also creates contrasting require-
ments for research versus clinical consent, questions concern-
ing use of a clinical versus research laboratory, and decisions
about whether to record results in the research or clinical
record. In CSER studies striving to establish the clinical utility
of sequencing and determine how best to integrate sequencing
into clinical care, the traditional dichotomy between research
and clinical care may be difficult to apply.
Second, in the context of CSER studies, disclosing results
serves multiple purposes—advancing knowledge on how to
communicate findings and sharing results that may have
direct clinical relevance. In this context, the issue is not so
much the sometimes-debated question of whether returning
research results conflates research with clinical care, as it is
what scope of findings should be returned. Should disclosure
stop with findings that are well understood and clinically
significant, or include more uncertain results? Individual
research projects may set the scope of return differently.19
Third, is the IRB—an oversight body for research—the right
body to oversee what results are returned in these studies for
the purposes of clinical care? The results may originate in
research studies, but the questions raised by patient access to
and clinical use of well-validated and clinically significant
results from a CLIA-certified lab go beyond research design,
and even the ancillary care obligations of investigators,28 to
questions of appropriate clinical care. It may be useful to turn
to specialized bodies such as Informed Cohort Oversight
Boards dedicated to handling return-of-results questions to
augment IRB oversight of research procedures.29,30
Finally, does translational merger of research and clinical
care have implications for insurance coverage and malpractice
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liability exposure? Both customarily attach only in domains of
clinical care. Yet the rapid progress of genomics in establish-
ing the significance of genomic variants in diagnosis and
care31,32 suggests that new mechanisms are needed to support
patient access while creating appropriate expectations for
responsible clinical implementation.33
Limitations
This analysis is based on survey responses from nine studies,
all of which participate in the CSER Consortium. Although
these studies were designed independently and survey
responses indicate a range of perspectives, the consortium
has served as a platform for collaboration. Thus, a survey
extending beyond the consortium might reveal a wider range
of views. In addition, the survey considered only projects
focusing on genome and exome sequencing. Comparison to
the views of investigators navigating the research–clinical
interface in other domains of translational research is an
essential next step.
Conclusion
Surveying investigators on the cutting edge of genomics
implementation reveals challenges at the research–clinical
interface, as well as a range of strategies for meeting
those challenges. More importantly, analysis of how these
investigators characterize that interface suggests that the
traditional dichotomous approach is now part of a broader
continuum of perspectives including merger of research
and clinical care. This poses fundamental challenges to the
conduct, ethics, and oversight of both research and clinical
care in translational genomics.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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